Congress clears FDA to reorganize Office of New Drugs

Congress has cleared the FDA to reorganize its Office of New Drugs (OND). The FDA plans to increase the number of clinical offices and divisions and group them by therapeutic area, enabling it to assign cross-functional teams to new drug applications (NDAs) at the start of the review process.